文献速递神经重症与神经感染

地塞米松辅助治疗成人单纯疱疹病毒性脑炎的安全性和有效性

Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial.
PubMed 文献 · Lancet Neurol · 2026-01-01

这项多中心、观察者盲、随机、3期对照试验纳入94例英国成人HSV脑炎患者,比较地塞米松联合阿昔洛韦与单用阿昔洛韦。地塞米松安全性可接受,但未改善言语记忆。

要点

  • 地塞米松联合阿昔洛韦未改善26周言语记忆评分。
  • 地塞米松组与对照组不良事件发生率相似(40% vs 38%)。
  • 无治疗相关死亡,地塞米松安全性可接受。

核心结论

  • 在成人HSV脑炎中,地塞米松联合阿昔洛韦安全性可接受,但未改善言语记忆评分。

研究设计与样本

  • 多中心、观察者盲、随机、3期对照试验,在英国53家医院纳入94例成人HSV脑炎患者。
  • 随机分配至地塞米松联合阿昔洛韦组(47例)或单用阿昔洛韦组(47例)。
  • 主要结局为26周时WMS-IV听觉记忆指数言语记忆评分,改良意向性分析纳入81例。

主要发现

  • 对照组18例(38%)发生27起不良事件,地塞米松组18例(40%)发生25起不良事件。
  • 常见严重不良事件包括需再入院癫痫发作(两组各1例[2%])和血栓事件(地塞米松组深静脉血栓1例[2%]、肺栓塞1例[2%])。
  • 无治疗相关死亡。

临床怎么用

  • 地塞米松联合阿昔洛韦安全性可接受,但不应期望其改善言语记忆预后。
  • 鉴于皮质激素在其他炎性脑炎中的作用,疑似脑炎早期使用可能无害。

局限性

  • 7例撤回知情同意,6例失访,改良意向性分析仅纳入81例。
  • 地塞米松启动时间为入院后中位7天(IQR 4-8),非早期使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Herpes simplex virus (HSV) encephalitis is characterised by inflammation and swelling of the brain, resulting in death or severe neurocognitive sequelae. HSV encephalitis is treated with the antiviral aciclovir but still has substantial mortality and morbidity. Adjunct corticosteroids are sometimes used, but whether they improve the outcome is unclear. We aimed to establish the safety and efficacy of adjunct corticosteroids in HSV encephalitis. METHODS: In this multicentre, observer-blind, randomised, phase 3 trial, adults with HSV encephalitis admitted to 53 hospitals in the UK were randomly assigned to receive intravenous dexamethasone (10 mg/kg, four times daily for 4 days) plus intravenous aciclovir (10 mg/kg three times daily for at least 14 days; dexamethasone group), or intravenous aciclovir alone (control group). Eligible patients aged 16 years or older had suspected encephalitis (a febrile illness with new onset seizure, new focal neurological signs or alteration in consciousness, cognition, personality, or behaviour), with positive HSV type 1 or type 2 PCR test in CSF. Participants were randomly assigned by the trial team at the recruiting site, using a secure web-based randomisation programme. The primary outcome was verbal memory score at 26 weeks, measured by the Wechsler Memory Scale (WMS)-IV auditory memory index. Analyses of primary and secondary outcomes were performed according to the modified intention-to-treat principle, and safety analyses were based on whether participants received at least one dose of the study drug. Trial neuropsychologists assessing the primary outcome, and statisticians involved in the study's primary outcome, were masked to treatment group allocation. The trial is registered with the International Standard Randomised Controlled Trial Number Registry, ISRCTN11774734, and EudraCT, EudraCT2016-004835-19, and is completed. FINDINGS: Between Sept 22, 2016, and Feb 2, 2022, 94 patients with HSV encephalitis were recruited, 47 (20 [43%] female and 27 [57%] male) to the dexamethasone group, and 47 (24 [51%] female and 23 [49%] male) to the control group. Dexamethasone was initiated a median 7 (IQR 4-8) days after hospital admission. Seven patients withdrew consent, and six were lost to follow-up. Thus, 81 were included in the modified intention-to-treat analysis (39 in the treatment group and 42 in the control group). The primary outcome, verbal memory score at 26 weeks, did not differ significantly between the groups (71 [SD 26] in the dexamethasone group, and 69 [SD 25] in the control group; adjusted difference 1·77 [95% CI -9·57 to 13·12; p=0·76). There were 27 adverse events involving 18 (38%) participants in the control group, and 25 adverse events involving 18 (40%) participants in the dexamethasone group. The most common serious adverse events were seizures requiring readmission to hospital (affecting one [2%] patient in the dexamethasone group and one [2%] patient in the control group) and thrombotic events, including deep vein thrombosis (affecting one [2%] patient in the dexamethasone group) and pulmonary embolism (affecting one [2%]patient in the dexamethasone group). There were no treatment-related deaths. INTERPRETATION: In adults with HSV encephalitis, dexamethasone plus aciclovir had a satisfactory safety profile but did not improve verbal memory score compared with aciclovir alone. Given the established role of corticosteroids in other inflammatory encephalitides, our findings suggest that their early use in suspected encephalitis is unlikely to be harmful. Future studies should assess more targeted immunomodulatory approaches in HSV encephalitis. FUNDING: National Institute for Health and Care Research.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Solomon T, Hooper C, Easton A, et al. Safety and efficacy of adjunct dexamethasone in adults with herpes simplex virus encephalitis in the UK (DexEnceph): a multicentre, observer-blind, randomised, phase 3, controlled trial. Lancet Neurol. 2026. PMID: 41579900. doi:10.1016/S1474-4422(25)00454-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。